- Laquinimod - complete results from Allegro Phase III trial presented
- TASQ - Active Biotech and Ipsen enter into a broad partnership for the co-development and commercialization of TASQ in uro-oncology
- ANYARA - ongoing Phase III study expected to be concluded in 2012
- 57-57 - orphan drug status granted
- ISI - project proceeding according to plan
- RhuDex(TM) - preparations for continued clinical development in progress
- Net sales SEK 2.7 M (2.8)
- Operating loss SEK 70.9 M (loss: 51.0)
- Loss after tax SEK 69.3 (loss: 53.5)
- Loss per share for the period amounted to 1.02 (loss: 0.83)
- Private placement of SEK 375 M completed
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54
Hans Kolam
CFO
Tel. +46 (0)46-19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
